MAS Predictors and Treatment Outcomes in Adult-Onset Still's Disease

Identifying reliable macrophage activation syndrome predictors is crucial for managing adult-onset Still's disease (AOSD). This rare autoinflammatory condition presents significant clinical challenges for physicians globally. Consequently, recognizing early warning signs is vital to prevent life-threatening complications. A recent long-term study evaluated 93 adult patients to determine effective treatments and risk factors. Specifically, researchers focused on clinical markers that signal disease progression and potential system failure.

The study showed that anakinra and tocilizumab offer similar efficacy in clinical settings. Both biological agents achieved a positive response in more than half of the patient cohort. However, if a patient fails anakinra therapy, switching to tocilizumab often proves successful. Indeed, eleven out of sixteen patients achieved complete remission after making this therapeutic transition. Therefore, clinicians should consider alternating biologics when initial cytokine-targeting therapies fail to reach remission targets.

Importance of Macrophage Activation Syndrome Predictors

Diagnostic delay significantly impacts long-term patient outcomes in AOSD. Furthermore, a longer interval between symptom onset and diagnosis leads to a poorer response to methotrexate. Similarly, these patients often struggle to discontinue glucocorticoids successfully. Most importantly, the research identified specific macrophage activation syndrome predictors that warrant close attention. High serum ferritin levels and the presence of lymphadenopathy are major risk indicators for MAS. Therefore, monitoring these parameters allows for timely intervention, which is essential for improving overall survival rates.

FAQs

Which biologics treat adult-onset Still's disease?

Anakinra and tocilizumab are the primary biologics used for refractory AOSD. They provide similar clinical response rates, ranging between 55% and 58%. Patients unresponsive to one often respond well to the other.

What are common macrophage activation syndrome predictors in AOSD?

The most reliable macrophage activation syndrome predictors include significantly elevated serum ferritin and the clinical presence of lymphadenopathy. Early identification of these markers helps clinicians initiate aggressive treatment sooner.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Acar B et al. Treatment outcomes and predictors of macrophage activation syndrome in adult-onset Still's disease: a 24 year single-centre experience. Scand J Rheumatol. 2026 Apr 28. doi: 10.1080/03009742.2026.2656045. PMID: 42047181.

Ruscitti P, Giacomelli R, Cipriani P, et al. M-CSF and IL-18 as potential biomarkers for Macrophage Activation Syndrome in Adult-onset Still's Disease. Rheumatology (Oxford). 2020;59(12):3743-3749.

Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult-onset Still's disease. J Autoimmun. 2018;93:24-36.